Julie E Chang

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint Therapeutic advances in the treatment of brain metastases
    Julie E Chang
    Hematology and Oncology Fellow, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Clin Adv Hematol Oncol 5:54-64. 2007
  2. ncbi request reprint Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme
    Julie E Chang
    Department of Medicine, Section of Hematology and Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Clin Adv Hematol Oncol 5:894-902, 907-15. 2007
  3. doi request reprint Current status of targeted therapies for mantle cell lymphoma
    Julie E Chang
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Drugs 71:2307-26. 2011

Detail Information

Publications3

  1. ncbi request reprint Therapeutic advances in the treatment of brain metastases
    Julie E Chang
    Hematology and Oncology Fellow, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Clin Adv Hematol Oncol 5:54-64. 2007
    ..Systemic agents showing activity in brain metastases including temozolomide, RSR13, motexafin gadolinium, and lapatinib are being explored...
  2. ncbi request reprint Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme
    Julie E Chang
    Department of Medicine, Section of Hematology and Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Clin Adv Hematol Oncol 5:894-902, 907-15. 2007
    ....
  3. doi request reprint Current status of targeted therapies for mantle cell lymphoma
    Julie E Chang
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Drugs 71:2307-26. 2011
    ..Although many of the agents appear to have modest single-agent activity, the favourable toxicity profile of many agents will make them best suited for incorporation into combination regimens...